View the latest news and SEC filings
Scroll to
LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024: Piper Sandler 36 th Annual Healthcare Conference Date:
LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m.
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population Pipeline expansion continues: Phase 2 programs enrolling Conference
LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
November 18, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
November 14, 2024 |
An amendment to the SC 13G filing |
SC 13G/A |
Other |
|
|
November 14, 2024 |
An amendment to the SC 13G filing |
SC 13G/A |
Other |
|
|
November 14, 2024 |
A statement of beneficial ownership of common stock by certain persons |
SC 13G |
Other |
|
|
November 14, 2024 |
An amendment to the SC 13G filing |
SC 13G/A |
Other |
|
|
November 13, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
November 13, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
November 13, 2024 |
An amendment to the SC 13G filing |
SC 13G/A |
Other |
|
|
November 12, 2024 |
Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing |
144 |
Other |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
